Sparsentan after approval: Defining the treatment boundary in FSGS without nephrotic syndrome
Nefrología · 2026-11 · 46 (9) · 501596
DOI: 10.1016/j.nefro.2026.501596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nefrología, 2026-11. Verfasst von Lucas Maciel de Almeida Corrêa und 8 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The US Food and Drug Administration approval of sparsentan to reduce proteinuria in adults and children aged 8 years or older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome represents a regulatory and therapeutic milestone, but also creates a new clinical challenge: how to translate a US proteinuria-based indication into phenotype-driven practice without treating FSGS as a single disease. DUPLEX established a robust antiproteinuric effect compared with irbesartan, but did not demonstrate a statistically significant between-group difference in eGFR slope at 108 weeks, underscoring the need for careful patient selection. This Perspective argues that the main post-approval task is to define a treatment boundary. Accordingly, sparsentan is best positioned not as a broad FSGS therapy, but as a nonimmunosuppressive antiproteinuric strategy for a delimited phenotype: biopsy-confirmed FSGS, persistent clinically relevant proteinuria, absence of overt nephrotic syndrome, and no clear indication for intensive immunosuppression. Primary nephrotic, secondary/adaptive, genetic, and advanced chronicity-dominant phenotypes require different therapeutic reasoning. We propose a practical framework integrating syndrome definition, exclusion of secondary drivers, genetic assessment, histologic chronicity, early proteinuria response, and safety monitoring. The clinical value of sparsentan in FSGS will depend less on broad adoption than on careful identification of patients in whom proteinuria reduction is likely to reflect a meaningful therapeutic target rather than a nonspecific pharmacodynamic effect.
Zitieren
APA
Corrêa, L. M. D. A., Brandão, L. K. V., Silva, Y. R. D., Fernandes, C. C. S., Pinheiro, I. M., Silva, É. V. B. D., Fossati, G. W., Meneses, M. C. D. N., & Arruda, S. L. P. (2026). Sparsentan after approval: Defining the treatment boundary in FSGS without nephrotic syndrome. Nefrología, 46(9), 501596. https://doi.org/10.1016/j.nefro.2026.501596
Vancouver
Corrêa LMDA, Brandão LKV, Silva YRD, Fernandes CCS, Pinheiro IM, Silva ÉVBD, et al. Sparsentan after approval: Defining the treatment boundary in FSGS without nephrotic syndrome. Nefrología. 2026;46(9):501596. doi:10.1016/j.nefro.2026.501596
BibTeX
@article{Corra2026,
author = {Corrêa, Lucas Maciel de Almeida and Brandão, Luiggi Kevin Virgino and Silva, Yan Roberth Delmiro and Fernandes, Camilla Cristina Silva and Pinheiro, Isabela Malerba and Silva, Éverton Victor Belmiro da and Fossati, Gabriela Wander and Meneses, Maria Clara do Nascimento and Arruda, Sicilia Lins Peixoto},
title = {Sparsentan after approval: Defining the treatment boundary in FSGS without nephrotic syndrome},
journal = {Nefrología},
year = {2026},
volume = {46},
number = {9},
pages = {501596},
doi = {10.1016/j.nefro.2026.501596}
}
EUVIMED